Terconazole Cream

Pronunciation: ter-KON-a-zole
Generic Name: Terconazole
Brand Name: Terazol

Terconazole Cream is used for:

Treating vaginal yeast infections in women. It may also be used for certain conditions as determined by your doctor.

Terconazole Cream is an antifungal agent. It works by weakening the fungal cell membrane, thereby killing sensitive fungi that cause yeast infections.

Do NOT use Terconazole Cream if:

• you are allergic to any ingredient in Terconazole Cream

Contact your doctor or health care provider right away if any of these apply to you.

Before using Terconazole Cream:

Some medical conditions may interact with Terconazole Cream. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of liver disease

Some MEDICINES MAY INTERACT with Terconazole Cream. However, no specific interactions with Terconazole Cream are known at this time.

Ask your health care provider if Terconazole Cream may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Terconazole Cream:

Use Terconazole Cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• An extra patient leaflet is available with Terconazole Cream. Talk to your pharmacist if you have questions about this information.


• Remove cap from tube. Reverse cap and place puncture tip onto tube. Push cap firmly until tube end is punctured.


• Screw applicator onto tube. Squeeze tube forcing contents into barrel until it is full.


• Then remove applicator from tube. Hold tube with attached applicator up. Squeeze tube from bottom until medication fills applicator. Remove applicator from tube.


• Lie on your back with knees drawn up. Hold filled applicator by barrel and gently insert it into the vagina as far as it will go comfortably. Press plunger and deposit material. While keeping plunger depressed, remove the applicator from vagina.


• After each use, pull applicator apart and wash with soap and warm water. An unclean applicator may not function properly. Thoroughly clean the applicator after each use.


• To clear up your infection completely, use Terconazole Cream for the full course of treatment. Keep using it even if you feel better in a few days.


• If you miss a dose of Terconazole Cream, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Terconazole Cream.

Important safety information:

• If your sexual partner has any penile itching, redness, or discomfort, he should consult his health care provider and mention that you are being treated for a yeast infection.


• You can use the medication even if you are having your menstrual period. However, you should not use tampons because they may absorb the medication. Instead, use external pads or napkins until you have finished your medication. You may also wish to wear a sanitary napkin if the vaginal medicine leaks.


• Dry the genital area thoroughly after showering, bathing, or swimming. Change out of a wet bathing suit or damp exercise clothes as soon as possible. A dry environment is less likely to encourage the growth of yeast.


• Wipe from front to rear (away from the vagina) after a bowel movement.


• Do not douche unless your doctor specifically tells you to do so. Douching may disturb the vaginal balance.


• Do not scratch the affected area if you can avoid it. Scratching can cause more irritation and spread the infection.


• If you have sexual intercourse during treatment, you may increase the risk of reinfection.


• Terconazole Cream may decrease the effectiveness of condoms and diaphragms.


• Be sure to use Terconazole Cream for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The fungus could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.


• Use Terconazole Cream with caution in the ELDERLY; they may be more sensitive to its effects.


• Terconazole Cream should not be used in CHILDREN; safety and effectiveness in children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Terconazole Cream while you are pregnant. It is not known if Terconazole Cream is found in breast milk. Do not breast-feed while taking Terconazole Cream.

Possible side effects of Terconazole Cream:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Body pain; burning or itching of the vagina; painful menstruation; stomach pain.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chills; flu-like symptoms (headache; tiredness; muscle aches; fever); vaginal sensitivity or irritation.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Terconazole side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of Terconazole Cream:

Store Terconazole Cream at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Terconazole Cream out of the reach of children and away from pets.

General information:

• If you have any questions about Terconazole Cream, please talk with your doctor, pharmacist, or other health care provider.


• Terconazole Cream is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Terconazole Cream. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Terconazole resources

• Terconazole Side Effects (in more detail)
• Terconazole Use in Pregnancy & Breastfeeding
• Terconazole Support Group
• 6 Reviews for Terconazole - Add your own review/rating

Compare Terconazole with other medications

• Vaginal Yeast Infection

Artandyl

Artandyl may be available in the countries listed below.

Ingredient matches for Artandyl

Trihexyphenidyl

Trihexyphenidyl is reported as an ingredient of Artandyl in the following countries:

• Hong Kong

International Drug Name Search

Thioplex

Generic Name: thiotepa (THYE oh TEP a)

Brand Names: Thioplex

What is Thioplex (thiotepa)?

Thiotepa is a cancer (antineoplastic) medication. Thiotepa interferes with the growth of cancer cells and slows their growth and spread in the body.

Thiotepa is used in the treatment of cancers of the breast, ovary, bladder, and others.

Thiotepa may also be used for purposes other than those listed in this medication guide.

What is the most important information I should know about Thioplex (thiotepa)?

Thiotepa should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.

Serious side effects have been reported with the use of thiotepa including: allergic reactions (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives); severe heart damage with prolonged use; decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; fever or chills; or signs of infection); severe nausea, vomiting, diarrhea, and loss of appetite; and others. Talk to your doctor about the possible side effects from treatment with thiotepa.

What should I discuss with my healthcare provider before using Thioplex (thiotepa)?

Do not use thiotepa without first talking to your doctor if you have

• kidney disease;


• liver disease; or


• 
  

  poor bone marrow function.

  
  

The use of thiotepa may be dangerous if you have any of the conditions listed above.

Thiotepa is in the FDA pregnancy category D. This means that thiotepa is known to be harmful to an unborn baby. Do not use thiotepa without first talking to your doctor if you are pregnant. Discuss with your doctor the appropriate use of birth control during treatment with thiotepa if either you or your partner is of childbearing potential. It is not known whether thiotepa passes into breast milk. Do not take thiotepa without first talking to your doctor if you are breast-feeding a baby. The safety and effectiveness of thiotepa in children has not been established.

How should I use Thioplex (thiotepa)?

Thiotepa should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.

Your doctor will determine the correct amount and frequency of treatment with thiotepa depending upon the type of cancer being treated and other factors. Talk to your doctor if you have any questions or concerns regarding the treatment schedule.

Your doctor will probably want you to have regularly scheduled blood tests and other medical evaluations during treatment with thiotepa to monitor progress and side effects.

Skin accidentally exposed to thiotepa should be rinsed thoroughly with soap and warm water.

Your healthcare provider will store thiotepa as directed by the manufacturer. If you are storing thiotepa at home, follow the directions provided by your healthcare provider.

What happens if I miss a dose?

Contact your doctor if you miss a dose of thiotepa.

What happens if I overdose?

If for any reason an overdose of thiotepa is suspected, seek emergency medical attention or contact your healthcare provider immediately.

Symptoms of a thiotepa overdose tend to be similar to side effects caused by the medication, although often more severe.

What should I avoid while using Thioplex (thiotepa)?

Thiotepa can lower the activity of your immune system making you susceptible to infections. Avoid contact with people who have colds, the flu, or other contagious illnesses and do not receive vaccines that contain live strains of a virus (e.g., live oral polio vaccine) during treatment with thiotepa. In addition, avoid contact with individuals who have recently been vaccinated with a live vaccine. There is a chance that the virus can be passed on to you.

Skin accidentally exposed to thiotepa should be rinsed thoroughly with soap and warm water.

Thioplex (thiotepa) side effects

If you experience any of the following serious side effects from thiotepa, seek emergency medical attention or contact your doctor immediately:

• 
  

  an allergic reaction (including difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);

  
  


• 
  

  decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);

  
  


• 
  

  tissue or vein reactions near the site of administration;

  
  


• 
  

  liver damage (abdominal pain, yellowing of the skin or eyes);

  
  


• 
  

  severe nausea, vomiting, or loss of appetite;

  
  


• 
  

  fever, chills, or other signs of infection; or

  
  


• 
  

  painful or difficult urination.

  
  

Other, less serious side effects may be more likely to occur. Continue taking thiotepa and talk to your doctor if you experience:

• 
  

  fatigue or weakness;

  
  


• 
  

  mild to moderate nausea, vomiting, or loss of appetite;

  
  


• 
  

  redness or inflammation of the eyes;

  
  


• 
  

  dizziness, headache, or blurred vision;

  
  


• 
  

  temporary hair loss;

  
  


• 
  

  a loss of skin coloration; or

  
  


• 
  

  decreased menstruation in women and decreased sperm production in men.

  
  

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Thioplex (thiotepa)?

Do not receive "live" vaccines during treatment with thiotepa. Administration of a live vaccine may be dangerous during treatment with thiotepa.

Drugs other than those listed here may also interact with thiotepa. Talk to your doctor and pharmacist before taking any other prescription or over-the-counter medicines, including herbal products, during treatment with thiotepa.

More Thioplex resources

• Thioplex Side Effects (in more detail)
• Thioplex Use in Pregnancy & Breastfeeding
• Thioplex Drug Interactions
• Thioplex Support Group
• 0 Reviews for Thioplex - Add your own review/rating

• Thioplex Advanced Consumer (Micromedex) - Includes Dosage Information


• Thiotepa Prescribing Information (FDA)


• Thiotepa Professional Patient Advice (Wolters Kluwer)


• Thiotepa MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Thioplex with other medications

• Bladder Cancer
• Breast Cancer
• Cancer
• Lymphoma
• Ovarian Cancer
• Serosal Cavity Neoplastic Disease

Where can I get more information?

• Your healthcare provider may have additional information about thiotepa that you may read.

See also: Thioplex side effects (in more detail)

Hytrin BPH 5mg Tablets

1. Name Of The Medicinal Product

Hytrin Tablets 5mg

Terazosin Tablets 5mg

2. Qualitative And Quantitative Composition

		mg/tablet
Active:	Terazosin as monohydrochloride dihydrate	5.0

3. Pharmaceutical Form

Tan, round, flat bevelled tablets embossed with logo and triangular facets on one face and plain on the other.

4. Clinical Particulars

4.1 Therapeutic Indications

Orally administered Hytrin is indicated in the treatment of mild to moderate hypertension. It may be used in combination with thiazide diuretics and/or other antihypertensive drugs or as sole therapy where other agents are inappropriate or ineffective. The hypotensive effect is most pronounced on the diastolic pressure. Although the exact mechanism of the hypotensive action of terazosin is not established, the relaxation of peripheral blood vessels appears to be produced mainly by competitive antagonism of post-synaptic alpha₁ - adrenoceptors. Hytrin usually produces an initial gradual decrease in blood pressure followed by a sustained antihypertensive action.

Orally administered Hytrin is also indicated as a therapy for the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia (BPH). Terazosin is a selective post synaptic alpha-1 -adrenoreceptor antagonist. Antagonism of alpha-i -receptors on prostatic and urethral smooth muscle has been shown to improve urinary tract flow and relieve the urinary obstruction caused by BPH.

4.2 Posology And Method Of Administration

Hypertension.

Adults

Initial dose

1 mg before bedtime is the starting dose for all patients and should not be exceeded. Compliance with this initial dosage recommendation should be strictly observed to minimise potential for acute first-dose hypotensive episodes.

Subsequent doses

The single daily dosage may be increased by approximately doubling the dosage at weekly intervals to achieve the desired blood pressure response.

The usual maintenance dose is 2mg to 10mg once daily. Doses over 20mg rarely improve efficacy and doses over 40mg have not been studied.

BPH

Adults Only:

The dose of terazosin should be adjusted according to the patient's response. The following is a guide to administration:

Initial dose

1 mg before bedtime is the starting dose for all patients and should not be exceeded. Strict compliance with this recommendation should be observed to minimise acute first-dose hypotensive episodes.

Subsequent dose

The dose may be increased by approximately doubling at weekly or bi-weekly intervals to achieve the desired reduction in symptoms. The maintenance dose is usually 5 to 10mg once daily. Improvements in symptoms have been detected as early as two weeks after starting treatment with terazosin.

At present there are insufficient data to suggest additional symptomatic relief with doses above 10mg once daily.

Treatment should be initiated using the BPH Starter Pack and response to treatment reviewed at four weeks. Transient side effects may occur at each titration step. If any side effects persist, consideration should be given to reducing the dose.

Use in renal insufficiency

Pharmacokinetic studies indicate that patients with impaired renal function need no alteration in the recommended dosages.

Use in Children

Safety and efficacy in children has not been established.

Use in the Elderly

Pharmacokinetic studies in the elderly indicate that no alteration in dosage recommendation is required.

Postural Hypotension

Postural hypotension has been reported to occur in patients receiving terazosin for the symptomatic treatment of urinary obstruction caused by BPH. In these cases, the incidence of postural hypotensive events was greater in patients aged 65 years and over (5.6%) than those aged less than 65 years (2.6%)

Use with thiazide diuretics and other antihypertensive agents

When adding a thiazide diuretic or another antihypertensive agent to a patient's regimen the dose of Hytrin should be reduced and retitration carried out if necessary. Caution should be observed when Hytrin is administered with thiazides or other antihypertensive agents as hypotension may develop.

4.3 Contraindications

Known sensitivity to alpha-adrenoceptor antagonists.

4.4 Special Warnings And Precautions For Use

As with other alpha adrenoreceptor antagonists, terazosin is not recommended in patients with a history of micturition syncope.

In clinical trials, the incidence of postural hypotension was greater in BPH patients than those with hypertension. In these cases, the incidence of postural hypotension events was greater in patients aged 65 years and over (5.6%) than those aged less than 65 years (2.6%).

If administration is discontinued for more than several days, therapy should be re-instituted using the initial dosing regimen.

Concomitant use of phosphodiesterase-5-inhibitors (e.g. sildenafil, tadalafil, vardenafil) and terazosin may lead to symptomatic hypotension in some patients. In order to minimise the risk for developing postural hypotension the patient should be stable on the alpha-blocker therapy before initiating use of phosphodiesterase-5-inhibitors.

The 'Intraoperative Floppy Iris Syndrome' (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin. Isolated reports have also been received with other alpha-1 blockers and the possibility of a class effect cannot be excluded. As IFIS may lead to increased procedural complications during cataract operation current or past use of alpha-1 blockers should be made known to the ophthalmic surgeon in advance of surgery.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

In patients receiving terazosin plus ACE inhibitors or diuretics the proportion reporting dizziness or related side effects was greater than in the total population of terazosin treated patients from clinical trials.

Caution should be observed when terazosin is administered with other antihypertensive agents, to avoid the possibility of significant hypotension. When adding terazosin to a diuretic or other antihypertensive agent, dosage reduction and retitration may be necessary.

Terazosin has been given without interaction with analgesics/anti-inflammatories, cardiac glycosides, hypoglycemics, antiarrhythmics, anxiolytics/sedatives, antibacterials, hormones/steroids and drugs used for gout.

Phosphodiesterase-5-inhibitors (e.g. sildenafil, tadalafil, vardenafil) (see section 4.4).

4.6 Pregnancy And Lactation

Although no teratogenic effects were seen in animal testing, the safety of Hytrin use during pregnancy or during lactation has not yet been established. Hytrin should not be used therefore in pregnancy unless the potential benefit outweighs the risk.

4.7 Effects On Ability To Drive And Use Machines

Dizziness, light-headedness or drowsiness may occur with the initial dose or in association with missed doses and subsequent reinitiation of Hytrin therapy. Patients should be cautioned about these possible adverse effects and the circumstances in which they may occur and advised to avoid driving or hazardous tasks for approximately 12 hours after initial dose or when the dose is increased.

4.8 Undesirable Effects

Hytrin in common with other alpha-adrenoceptor antagonists may cause syncope. Syncopal episodes have occurred within 30 to 90 minutes of the initial dose of the drug. Syncope has occasionally occurred in association with rapid dosage increases or the introduction of another antihypertensive agent.

In clinical trials in hypertension, the incidence of syncopal episodes was approximately one percent. In most cases this was believed to be due to an excessive postural hypotensive effect although occasionally the syncopal episode has been preceded by a bout of tachycardia with heart rates of 120 to 160 beats per minute.

If syncope occurs the patient should be placed in a recumbent position and supportive treatment applied as necessary.

Dizziness, light-headedness or fainting may occur when standing up quickly from a lying or sitting position. Patients should be advised of this possibility and instructed to lie down if these symptoms appear and then sit for a few minutes before standing to prevent their recurrence.

These adverse effects are self limiting and in most cases do not recur after the initial period of therapy or during subsequent re-titration.

Adverse events reported with terazosin

The most common events were asthenia, palpitations, nausea, peripheral oedema, dizziness, somnolence, nasal congestion/rhinitis and blurred vision/amblyopia.

In addition, the following have been reported: back pain; headache; tachycardia; postural hypotension; syncope; oedema; weight gain; pain in extremities; decreased libido; depression; nervousness; paraesthesia; vertigo; dyspnoea; sinusitis and impotence.

Additional adverse reactions reported in clinical trials or reported during marketing experience but not clearly associated with the use of terazosin include the following:

chest pain; facial oedema; fever; abdominal pain; neck pain; shoulder pain; vasodilation; arrhythmia; constipation; diarrhoea; dry mouth; dyspepsia; flatulence; vomiting; gout; arthralgia; arthritis; joint disorders; myalgia; anxiety; insomnia; bronchitis; epistaxis; flu symptoms; pharyngitis; rhinitis; cold symptoms; pruritis; rash; increased cough; sweating; abnormal vision; conjunctivitis; tinnitus; urinary frequency; urinary tract infection and urinary incontinence primarily reported in post-menopausal women.

At least two cases of anaphylactoid reactions have been reported with the administration of terazosin.

Post marketing experience: Thrombocytopenia and priapism have been reported. Atrial fibrillation has been reported: however, a cause and effect relationship has not been established.

Laboratory tests: Small but statistically significant decreases in haematocrit, haemoglobin, white blood cells, total protein and albumin were observed in controlled clinical trials. These laboratory findings suggest the possibility of haemodilution. Treatment with terazosin for up to 24 months had no significant effect on prostate specific antigen (PSA) levels.

4.9 Overdose

Should administration of Hytrin lead to acute hypotension, cardiovascular support is of first importance. Restoration of blood pressure and normalisation of heart rate may be accomplished by keeping the patient in a supine position. If this measure is inadequate, shock should first be treated with volume expanders and if necessary, vasopressors could then be used. Renal function should be monitored and general supportive measures applied as required. Dialysis may not be of benefit since laboratory data indicate that terazosin is highly protein bound.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

Although the exact mechanism of the hypotensive action is not established, the relaxation of peripheral blood vessels appears to be produced mainly by competitive antagonism of post-synaptic alpha-adrenoceptors. Hytrin usually produces an initial gradual decrease in blood pressure followed by a sustained antihypertensive action.

Clinical experience indicates that a 2-5% decrease in total cholesterol plasma concentration and a 3-7% decrease in the combined LDL_C + VLDL_C fraction plasma concentration from pretreatment values are associated with the administration of therapeutic doses of terazosin.

In clinical trials, plasma concentrates of total cholesterol and combined low density and very low density lipoproteins were found to be slightly reduced following Hytrin administration. Additionally, the increase in total cholesterol seen with other hypertensive agents did not occur when these were used in combination with Hytrin.

Studies suggest that alpha-1 -adrenoreceptor antagonism is useful in improving the urodynamics in patients with chronic bladder obstruction such as in benign prostatic hyperplasia (BPH).

The symptoms of BPH are caused mainly by the presence of an enlarged prostate and by the increased smooth muscle tone of the bladder outlet and prostate, which is regulated by alpha-1 -adrenergic receptors.

In in-vitro experiments, terazosin has been shown to antagonise phenylephrine-induced contractions of human pro static tissue. In clinical trials terazosin has been shown to improve the urodynamics and symptomatology in patients with BPH.

5.2 Pharmacokinetic Properties

The plasma concentration of the parent drug is a maximum about 1 hour post administration and declines with a half-life of approximately 12 hours. Food has little or no effect on bioavailability. Approximately 40% of the administered dose is eliminated in the urine and 60% in the faeces. The drug is highly bound to plasma proteins.

5.3 Preclinical Safety Data

Carcinogenicity: Hytrin has been shown to produce tumours in male rats when administered at a high dose over a long period of time. No such occurrences were seen in female rats or in a similar study in mice. The relevance of these findings with respect to the clinical use of the drug in man is unknown.

6. Pharmaceutical Particulars

6.1 List Of Excipients

Lactose

Maize starch

Pregelatinised starch

Purified talc

Magnesium stearate

Purified water

Dye (iron oxide burnt sienna, E172)

6.2 Incompatibilities

None known.

6.3 Shelf Life

36 months.

6.4 Special Precautions For Storage

None.

6.5 Nature And Contents Of Container

Tablets in a blister original pack. The 5mg tablets are supplied in a pack of 28 tablets. Blisters are packaged in a carton with a package insert.

Starter pack for BPH:

Tablets in a blister pack. The starter pack consists of 7 x 1mg, 14 x 2mg and 7 x 5mg tablets. The blisters, of PVC/PVdC, are heat sealed with 20 micron hard tempered aluminium foil and packaged in a carton with a pack insert.

6.6 Special Precautions For Disposal And Other Handling

Not applicable.

7. Marketing Authorisation Holder

Amdipharm plc

Regency House

Miles Gray Road

Basildon

Essex

SS14 3AF

8. Marketing Authorisation Number(S)

PL 20072/0030

9. Date Of First Authorisation/Renewal Of The Authorisation

13/05/97

10. Date Of Revision Of The Text

June 2009

Epi-Stat

Generic Name: barium sulfate (Oral route, Rectal route)

BAR-ee-um SUL-fate

Commonly used brand name(s)

In the U.S.

• Bar-Test


• E-Z-Disk


• Readi-Cat


• Volumen

In Canada

• Acb


• Baro-Cat


• Barosperse Enema


• Colobar-100


• Epi-C


• Epi-Stat


• Esobar


• Esopho-Cat Esophageal Cream


• E-Z-Cat


• E-Z-Hd


• E-Z-Jug


• E-Z-Paque

Available Dosage Forms:

• Kit


• Suspension


• Powder for Suspension


• Enema


• Paste


• Tablet


• Liquid

Therapeutic Class: Diagnostic Agent, Radiological Contrast Media

Uses For Epi-Stat

Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.

Barium sulfate is taken by mouth or given rectally by enema. If taken by mouth, it makes the esophagus, the stomach, and/or the small intestine opaque to the x-rays so that they can be "photographed". If it is given by enema, the colon and/or the small intestine can be seen and photographed by x-rays.

The dose of barium sulfate will be different for different patients and depends on the type of test. The strength of the suspension and tablet is determined by how much barium they contain. Different tests will require a different strength and amount of suspension (some may require the tablet form), depending on the age of the patient, the contrast needed, and the x-ray equipment used.

Barium sulfate is to be used only by or under the direct supervision of a doctor.

Before Using Epi-Stat

In deciding to use a diagnostic test, any risks of the test must be weighed against the good it will do. This is a decision you and your doctor will make. Also, other things may affect test results. For this test, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Although there is no specific information comparing use of barium sulfate in children with use in other age groups, this agent is not expected to cause different side effects or problems in children than it does in adults.

Geriatric

This contrast agent has been used in older people and has not been shown to cause different side effects or problems in them than it does in younger adults.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of this diagnostic test. Make sure you tell your doctor if you have any other medical problems, especially:

• Asthma, hay fever, or other allergies (history of)—If you have a history of these conditions, the risk of having a reaction, such as an allergic reaction to the additives in the barium sulfate preparation, is greater

• Cystic fibrosis—The risk of blockage in the small bowel is greater

• Dehydration—Barium sulfate may cause severe constipation

• Intestinal blockage or perforation—Barium sulfate may make this condition worse

Proper Use of barium sulfate

This section provides information on the proper use of a number of products that contain barium sulfate. It may not be specific to Epi-Stat. Please read with care.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

Precautions While Using Epi-Stat

Make sure to drink plenty of liquids after the test. Otherwise, barium sulfate may cause severe constipation.

Epi-Stat Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Rare

• Bloating


• constipation (severe, continuing)


• cramping (severe)


• nausea or vomiting


• stomach or lower abdominal pain


• tightness in chest or troubled breathing


• wheezing

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Constipation or diarrhea


• cramping

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Epi-Stat side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Epi-Stat resources

• Epi-Stat Side Effects (in more detail)
• Epi-Stat Use in Pregnancy & Breastfeeding
• Epi-Stat Support Group
• 1 Review for Epi-Stat - Add your own review/rating

Compare Epi-Stat with other medications

• Computed Tomography

Irinotecan Pliva

Irinotecan Pliva may be available in the countries listed below.

Ingredient matches for Irinotecan Pliva

Irinotecan

Irinotecan hydrochloride trihydrate (a derivative of Irinotecan) is reported as an ingredient of Irinotecan Pliva in the following countries:

• Croatia (Hrvatska)

International Drug Name Search

Tamoxifen AL

Tamoxifen AL may be available in the countries listed below.

Ingredient matches for Tamoxifen AL

Tamoxifen

Tamoxifen citrate (a derivative of Tamoxifen) is reported as an ingredient of Tamoxifen AL in the following countries:

• Germany

International Drug Name Search